Slide 1: Investor Relations Conference Call
Investor Relations Conference Call January 14, 2008 simulations plus, inc. oe
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 3: Introduction and Welcome
Introduction and Welcome * Introduction and Welcome ¢ Agenda — First Fiscal Quarter FY 2008 summary — Strategy Going Forward — Questions and Answers simulations plus, inc. oe
Slide 4: First Fiscal Quarter 2008 Summary
First Fiscal Quarter 2008 Summary Gross revenues = $1.98 MM (up over 36% from 1Q07) — Pharmaceutical software and services = $1.438 MM (up 74.5% from 1Q07) + Large order received in November that was received in December last year + Pharmaceutical software and services business would have exceeded 1
Slide 5: Income Tax Discussion
Income Tax Discussion Tax returns are filed after the 10-K, so the taxes are estimated for the 10K filing, but sometimes change as the retums are prepared because of changes in rules for tax credits and other accounting factors, such as: — Last year, the Extraterritorial Income Exclusion expired, lo
Slide 6: Progress: ADMET Predictor/ADMET Modeler
Progress ¢ ADMET Predictor/ADMET Modeler — NIH SBIR grant completed and Phase II proposal submitted for $750,000 effort over two years * Very fast calculation of unique quantum mechanical descriptors has been shown to improve accuracy of several property predictions — Tighter integration of ADMET Pr
Slide 7: Progress: ClassPharmer and DDDPlus
Progress - 2 * ClassPharmer — Version 4.4 released with numerous improvements added in response to customer requests — Additional molecule design capabilities nearing release — Tighter integration with ADMET Predictor in progress ¢ DDDPlus — Sales increasing steadily, with customers now in U.S., Eur
Slide 8: Progress: GastroPlus
Progress - 3 GastroPlus — Version 5.3 released in October *« ADMET Predictor integration * Faster numerical integrator « Ability to handle new formulations * Monkey physiology added to existing human and animal models for physiologically based pharmacokinetics (PBPK) — New capabilities in developmen
Slide 9: Progress: Words+ subsidiary
Progress - 4 * Words+ subsidiary — New Say-it! SAM PDA-based communication system developed and release at end of the first quarter (injection molding issues held up project for several months) — strong reception to new product — New vocabularies for SAM communication software developed and released
Slide 10: Miscellaneous
Miscellaneous ¢ New on-site Life Sciences Director, Dr. John Crison, joined in September * New Ph.D. scientist joined us in January, replacing one who left to work at Pfizer * Acquisitions taking longer than expected, but we are still actively working on acquisitions for both the pharmaceutical busi
Slide 11: Strategy Going Forward
Strategy Going Forward ¢ Expand product line and services — Pharmaceutical software * Seek and complete strategic acquisition(s) * Continue to enhance current products * Seek opportunities to partner and/or acquire new products « Examine additional SBIR opportunities — Pharmaceutical consulting serv
Slide 12: Summary
Summary Company is financially strong with excellent cash position and no debt Revenues are up in the first quarter. — Major software license was renewed in November of this year instead of December — we expect this one will remain in November from now on — Pharmaceutical software and services reven
Slide 13: Questions?
Questions? simulations plus, inc. &